10-Q: Cognition Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Cognition Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs targeting age-related degenerative diseases.

Summary

• Cognition Therapeutics, Inc. reported a net loss of $8.48 million for the three months ended March 31, 2025, compared to a net loss of $9.151 million for the same period in 2024.
• Research and development expenses were $10.786 million, slightly up from $10.553 million in the prior year.
• General and administrative expenses decreased to $2.989 million from $3.549 million.
• Grant income increased to $5.086 million from $4.912 million.
• As of March 31, 2025, the company's cash and cash equivalents stood at $16.428 million, a decrease from $25.009 million at the end of 2024.
• The company believes its current cash and cash equivalents are not sufficient to fund operations for the next year, raising substantial doubt about its ability to continue as a going concern.
• Cognition Therapeutics is focused on developing disease-modifying treatments for age-related degenerative diseases, particularly Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
• Top-line results from the Phase 2 COG0201 SHINE study in mild-to-moderate AD showed that zervimesine was safe and tolerable, with a prespecified analysis identifying plasma p-tau217 as a potential biomarker for therapeutic response.
• Top-line results from the Phase 2 COG1201 SHIMMER study in DLB showed that zervimesine-treated patients scored better than placebo-treated patients on the neuropsychiatric inventory (NPI) A-L.
• The company voluntarily discontinued the Phase 2 COG2201 MAGNIFY study of zervimesine in adults with geographic atrophy secondary to dry AMD to focus resources on dementia programs.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's progress in clinical trials and a decrease in net loss compared to the previous year, the company's financial position raises concerns about its ability to continue as a going concern. The need for additional funding and the discontinuation of a clinical study further contribute to a cautious sentiment.

Positives

• The net loss for Q1 2025 was lower than the net loss for Q1 2024 ($8.48 million vs $9.151 million).
• Grant income increased from $4.912 million to $5.086 million year-over-year.
• The SHINE study met its primary endpoints of safety and tolerability.
• The SHIMMER study met its primary endpoints of safety and tolerability.
• The company has approximately $47.0 million available from obligated NIA funds for applicable expenses to be incurred in the future.
• The company has approximately $20.4 million remaining in gross proceeds available for future issuances of common stock under the ATM, subject to the limitations of General Instruction I.B.6 of Form S-3.
• As of March 31, 2025, $34.8 million was available to draw pursuant to the Lincoln Park Purchase Agreement.

Negatives

• The company has incurred recurring losses since inception and expects to continue to incur losses for the foreseeable future.
• The company has substantial doubt about its ability to continue as a going concern.
• Cash and cash equivalents decreased from $25.009 million at the end of 2024 to $16.428 million as of March 31, 2025.
• The company voluntarily discontinued the Phase 2 COG2201 MAGNIFY study of zervimesine in adults with geographic atrophy secondary to dry AMD.

Risks

• The company's ability to raise additional capital to fund operations and continue the development of product candidates is uncertain.
• The company's ability to maintain the listing of its common stock on the Nasdaq Capital Market is not guaranteed.
• The clinical development process is inherently uncertain, and the company's product candidates may not receive regulatory approval.
• The company is dependent on the success of zervimesine (CT1812), its lead product candidate.
• The company faces competition from other therapies that are or become available.
• Global political changes and global economic conditions, including inflation, tariffs, or uncertainty caused by political violence and unrest, including ongoing global and regional conflicts, could adversely affect the company's business.

Future Outlook

The company expects to continue to incur significant and increasing expenses and net losses for the foreseeable future as it advances its product candidates through clinical development and seeks regulatory approval. The company will need substantial additional funding to support its continuing operations and pursue its growth strategy.

Management Comments

• The company believes that its existing cash and cash equivalents, income from non-dilutive grants, and net proceeds from its March 2024 follow-on public offering will be sufficient for it to fund its operating expenses and capital expenditures requirements into the fourth quarter of 2025, which assumes no usage from the remaining ATM nor the Lincoln Park Purchase Agreement.

Industry Context

Cognition Therapeutics is operating in the biopharmaceutical industry, specifically targeting age-related degenerative diseases of the central nervous system and retina. The company's focus on Alzheimer's disease and dementia with Lewy bodies aligns with the growing need for effective treatments for these conditions, given the limited options currently available. The company's approach of targeting the -2 (sigma-2) receptor (S2R) complex represents a novel mechanism that is functionally distinct from other current approaches in clinical development.

Comparison to Industry Standards

• Cognition Therapeutics is developing treatments for Alzheimer's disease, a space where companies like Biogen, Eisai, and Eli Lilly are also heavily invested.
• The company's focus on the sigma-2 receptor (S2R) complex is a unique approach compared to the amyloid-beta and tau-targeting strategies of many competitors.
• The company's decision to discontinue the MAGNIFY study in geographic atrophy (GA) secondary to dry AMD reflects a strategic prioritization similar to how other biopharmaceutical companies manage their pipelines based on clinical data and resource allocation.
• The company's reliance on NIA grants for funding is a common practice among smaller biotech companies focused on neurodegenerative diseases, as government funding can help offset the high costs of clinical development.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be affected by potential cost-cutting measures if the company's financial situation does not improve.
• Patients with Alzheimer's disease and dementia with Lewy bodies could benefit from the successful development of zervimesine.
• The company's suppliers and CROs may be impacted by changes in the company's clinical development plans and funding.

Next Steps

• Continue enrolling participants in the Phase 2 COG0203 (START) study of zervimesine in patients with MCI or early AD.
• Pursue additional funding through public or private equity offerings, debt financings, or other sources, such as potential collaboration agreements and strategic alliances.
• Continue to seek non-dilutive research contributions, or grants, including additional NIA grant funding.

Key Dates

Keywords

Cognition Therapeutics, Zervimesine, Alzheimer's disease, Dementia with Lewy bodies, Clinical trials, Financial results, Biopharmaceutical, Neurodegenerative diseases, Research and development, NIA grant